15 Results for "

agonistic monoclonal

" in MedChemExpress (MCE) Product Catalog:
Products (15)

15 Results for "agonistic monoclonal" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-P990680
Anti-Mouse CD40 Antibody (FGK4.5/FGK45) is an agonistic rat-derived IgG2a monoclonal antibody targeting mouse CD40. Anti-Mouse CD40 Antibody (FGK4.5/FGK45) enhances T cells responses, dendritic cells maturation and NK cells activation. Anti-Mouse CD40 Antibody (FGK4.5/FGK45) can be used for the researches of cancer, infection, inflammation and immunology, such as CT26 tumor, vesicular stomatitis virus (VSV) infection and transplantation .
loading...
    loading...
Cat. No.: HY-P99049
CAS No.: 2305607-45-6
Synonyms: APX005M; APX005M; EPI-0050

Target:  

TNF Receptor

Research Areas:  

Inflammation/Immunology Cancer

Sotigalimab, a CD40 agonistic monoclonal antibody. Sotigalimab binds CD40 with high affinity and activates antigen-presenting cells, thereby stimulating cancer-specific T cell responses. Sotigalimab is mainly used in the study of metastatic pancreatic cancer and metastatic melanoma .
loading...
    loading...
Cat. No.: HY-P99286
CAS No.: 912628-39-8
Synonyms: PRO 95780; rhuMAb-DR 5; Anti-Human DR5 Recombinant Antibody

Target:  

Apoptosis

Research Areas:  

Cancer

Drozitumab (PRO 95780) is a human agonistic monoclonal antibody which binds the death receptor DR5. Drozitumab has potent antitumor activity against rhabdomyosarcoma .
loading...
    loading...
Cat. No.: HY-P99299
CAS No.: 845816-02-6
Synonyms: HGS-ETR 2; ETR2-ST01

Target:  

Apoptosis

Research Areas:  

Cancer

Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research .
loading...
    loading...
Cat. No.: HY-P99265
CAS No.: 658052-09-6
Synonyms: HGS-ETR1; Anti-Human TNFRSF10A Recombinant Antibody

Target:  

Inhibitory Antibodies

Research Areas:  

Cancer

Mapatumumab (HGS-ETR1) is a fully human IgG1 agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). Mapatumumab can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-P99603
CAS No.: 1629760-27-5
Synonyms: SEA-CD40

Target:  

Inhibitory Antibodies

Research Areas:  

Cancer

Cifurtilimab (SEA-CD40) is an agonistic nonfucosylated, human IgG1 monoclonal antibody directed against CD40. Cifurtilimab shows antitumor activities .
loading...
    loading...
Cat. No.: HY-P991052
CAS No.: 2089398-68-3

Target:  

TNF Receptor

Research Areas:  

Cancer

GSK-3174998 is a humanized IgG1 OX40/TNFRSF4 agonistic monoclonal antibody. GSK-3174998 has the potential for the study of advanced solid tumors. The isotype control for GSK-3174998 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
loading...
    loading...
Cat. No.: HY-P99119

Research Areas:  

Inflammation/Immunology Cancer

Anti-Mouse 4-1BB/CD137 Antibody (3H3) is an anti-mouse 4-1BB/CD137 IgG2a κ agonistic monoclonal antibody. Anti-Mouse 4-1BB/CD137 Antibody (3H3) can effectively activate memory T cells and inhibit tumors by increasing Bcl-xL and granzyme B levels. Anti-Mouse 4-1BB/CD137 Antibody (3H3) can be used for research on cancer such as lymphoma and colon cancer .
loading...
    loading...
Cat. No.: HY-P991402

Target:  

TNF Receptor NF-κB

Research Areas:  

Cancer

BI-1910 is an agonistic human IgG2 monoclonal antibody targeting TNFR2, which selectively binds to human TNFR2 without inhibiting TNF-α binding. As an endogenous agonist, BI-1910 activates TNFR2 and mediates the activation of the NF-κB signaling pathway. Its agonistic activity is independent of FcγR or cross-linking; it can directly costimulate T cells and NK cells, induce T cell proliferation, and activate tumor-specific CD8+ T cells. BI-1910 exhibits antitumor activity in vivo, and shows an additive antitumor effect when combined with anti-PD-1 (HY-P9902). It can be used in research related to advanced/metastatic non-small cell lung cancer and hepatocellular carcinoma. Recommended isotype control: Human IgG2 lambda, Isotype Control (HY-P991206) .
loading...
    loading...
Cat. No.: HY-P99640
CAS No.: 2226292-20-0
Synonyms: ABBV-927

Target:  

Inhibitory Antibodies

Research Areas:  

Cancer

Giloralimab (ABBV-927) is a potent antiCD40 agonistic monoclonal antibody. Giloralimab has the potential for the research of cancer .
loading...
    loading...
Cat. No.: HY-P991070

Target:  

TNF Receptor

Research Areas:  

Cancer

ADG-106 is a fully human agonistic monoclonal IgG4 antibody against CD137 (4-1BB). ADG-106 has the mechanism to activate CD137 via strong FcγRIIB-mediated crosslinking while antagonizing CD137 ligands. The isotype control for ADG-106 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
loading...
    loading...
Cat. No.: HY-P9S0062
Rosnilimab (Mouse IgG2a) is a mouse-derived IgG2a antibody, Rosnilimab. Rosnilimab is a PD-1 agonistic monoclonal antibody. Rosnilimab (Mouse IgG2a) optimizes the inhibitory PD-1 signaling pathway without blocking PD-L1 binding; it also activates moderately activated PD-1 + T cells and eliminates PD-1 high cells, Tfh/Tph cells and Teff cells. Rosnilimab (Mouse IgG2a) reduces the secretion and gene expression of IFN-γ, CXCL13, IL-6 and TNF, decreases macrophage infiltration, and downregulates the gene expression of inflammatory myeloid cells. Rosnilimab (Mouse IgG2a) can be used in studies related to ulcerative colitis .
loading...
    loading...
Cat. No.: HY-P992044
Synonyms: NOV1801
EU101 (NOV1801) is a humanized agonistic monoclonal antibody targeting the costimulatory receptor CD137, with potential immunostimulatory and antineoplastic activities .
loading...
    loading...
Cat. No.: HY-P991528

Target:  

NF-κB

Research Areas:  

Inflammation/Immunology Cancer

PE0116 is a fully human CD137 agonistic monoclonal antibody generated from immunized harbor H2L2 human transgenic mice. PE0116 is a ligand block. PE0116 activates NF-κB signaling which significantly promotes T-cell proliferation and increases cytokine secretion in vitro. PE0116 exhibits robust antitumor activity in MC38 tumor model .
loading...
    loading...
Cat. No.: HY-P991530
YH004 is an anti-CD137 agonistic monoclonal antibody, with immunostimulating and antineoplastic activities. YH004 activates CD137 expressed on a variety of leukocyte subsets including activated T lymphocytes and natural killer cells. YH004 enhances CD137-mediated signaling and induces cytotoxic T-lymphocyte (CTL) proliferation, cytokine production and promotes anti-tumor response mediated by CTL. YH004 induces NK-mediated tumor cell killing and suppresses the immunosuppressive activity of regulatory T cells. YH004 can be studied in anticancer research .
loading...
    loading...
  • 1